Therapeutic targets: Progress of their exploration and investigation of their characteristics

被引:134
作者
Zheng, C. J. [1 ]
Han, L. Y. [1 ]
Yap, C. W. [1 ]
Ji, Z. L. [1 ]
Cao, Z. W. [1 ]
Chen, Y. Z. [1 ]
机构
[1] Natl Univ Singapore, Dept Computat Sci, Bioinformat & Drug Design Grp, Singapore, Singapore
关键词
D O I
10.1124/pr.58.2.4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Modern drug discovery is primarily based on the search and subsequent testing of drug candidates acting on a preselected therapeutic target. Progress in genomics, protein structure, proteomics, and disease mechanisms has led to a growing interest in and effort for finding new targets and more effective exploration of existing targets. The number of reported targets of marketed and investigational drugs has significantly increased in the past 8 years. There are 1535 targets collected in the therapeutic target database compared with similar to 500 targets reported in a 1996 review. Knowledge of these targets is helpful for molecular dissection of the mechanism of action of drugs and for predicting features that guide new drug design and the search for new targets. This article summarizes the progress of target exploration and investigates the characteristics of the currently explored targets to analyze their sequence, structure, family representation, pathway association, tissue distribution, and genome location features for finding clues useful for searching for new targets. Possible "rules" to guide the search for druggable proteins and the feasibility of using a statistical learning method for predicting druggable proteins directly from their sequences are discussed.
引用
收藏
页码:259 / 279
页数:21
相关论文
共 130 条
[61]   Molecular pathophysiology and targeted therapeutics for muscular dystrophy [J].
Hoffman, EP ;
Dressman, D .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (09) :465-470
[62]   The druggable genome [J].
Hopkins, AL ;
Groom, CR .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :727-730
[63]   New investigational antifungal agents for treating invasive fungal infections [J].
Hossain, MA ;
Ghannoum, MA .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) :1797-1813
[64]   SELECTIVE BETA-3-ADRENERGIC AGONISTS OF BROWN ADIPOSE-TISSUE AND THERMOGENESIS .1. [4-[2-[(2-HYDROXY-3-PHENOXYPROPYL)AMINO]ETHOXY]PHENOXY]ACETATES [J].
HOWE, R ;
RAO, BS ;
HOLLOWAY, BR ;
STRIBLING, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (10) :1751-1759
[65]   Emerging high-throughput drug target validation technologies [J].
Ilag, LL ;
Ng, JH ;
Beste, G ;
Henning, SW .
DRUG DISCOVERY TODAY, 2002, 7 (18) :S136-S142
[66]   Alzheimer disease therapeutics [J].
Irizarry, MC ;
Hyman, BT .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (10) :923-928
[67]   Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: Possible mechanisms of action [J].
Jabbour, E ;
Kantarjian, H ;
Cortes, J .
LEUKEMIA & LYMPHOMA, 2004, 45 (11) :2187-2195
[68]   Prediction of human protein function from post-translational modifications and localization features [J].
Jensen, LJ ;
Gupta, R ;
Blom, N ;
Devos, D ;
Tamames, J ;
Kesmir, C ;
Nielsen, H ;
Stærfeldt, HH ;
Rapacki, K ;
Workman, C ;
Andersen, CAF ;
Knudsen, S ;
Krogh, A ;
Valencia, A ;
Brunak, S .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 319 (05) :1257-1265
[69]  
Kanehisa M, 2002, NOVART FDN SYMP, V247, P91
[70]   Classifying G-protein coupled receptors with support vector machines [J].
Karchin, R ;
Karplus, K ;
Haussler, D .
BIOINFORMATICS, 2002, 18 (01) :147-159